Cargando…

Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure

OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Frangakis, Constantine, Sohn, Jae Ho, Bas, Ahmet, Chapiro, Julius, Schernthaner, Ruediger E., Lin, MingDe, Hamilton, James P., Pawlik, Timothy M., Hong, Kelvin, Duran, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602787/
https://www.ncbi.nlm.nih.gov/pubmed/34804911
http://dx.doi.org/10.3389/fonc.2021.639235
_version_ 1784601632625917952
author Frangakis, Constantine
Sohn, Jae Ho
Bas, Ahmet
Chapiro, Julius
Schernthaner, Ruediger E.
Lin, MingDe
Hamilton, James P.
Pawlik, Timothy M.
Hong, Kelvin
Duran, Rafael
author_facet Frangakis, Constantine
Sohn, Jae Ho
Bas, Ahmet
Chapiro, Julius
Schernthaner, Ruediger E.
Lin, MingDe
Hamilton, James P.
Pawlik, Timothy M.
Hong, Kelvin
Duran, Rafael
author_sort Frangakis, Constantine
collection PubMed
description OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient. RESULTS: No significant change in PC over time was observed in either groups, regardless of liver function (P>0.05). Baseline spleen volume was 226 cm(3) for metastatic group, and was larger by 204 cm(3) for HCC group (P<0.001). Spleen volume increased by 20 cm(3) (95%CI: 8-32; P=0.001) for both groups after 1(st)TACE and by 16cm(3)/TACE (P=0.099) over the full follow-up (up to 9TACEs). Spleen volume also tended to increase by 23cm(3) (95%CI: -1–48; P=0.064) with higher tumor burden. Odds of developing moderate/severe ascites for metastatic patients was decreased by 0.5 (95%CI: 0.3–0.9; P=0.014), regardless of the Child-Pugh, and increased by 1.5 (95%CI: 1.2–1.9; P<0.001) among HCC patients with unstable Child-Pugh, whereas no change was noted with stable Child-Pugh. HCC patients with unstable Child-Pugh demonstrated a significant increase in portosystemic collaterals number over time (P=0.008). PVP-related complications such as variceal bleeding post-TACE were low (0.4%). CONCLUSION: Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications.
format Online
Article
Text
id pubmed-8602787
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86027872021-11-20 Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure Frangakis, Constantine Sohn, Jae Ho Bas, Ahmet Chapiro, Julius Schernthaner, Ruediger E. Lin, MingDe Hamilton, James P. Pawlik, Timothy M. Hong, Kelvin Duran, Rafael Front Oncol Oncology OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient. RESULTS: No significant change in PC over time was observed in either groups, regardless of liver function (P>0.05). Baseline spleen volume was 226 cm(3) for metastatic group, and was larger by 204 cm(3) for HCC group (P<0.001). Spleen volume increased by 20 cm(3) (95%CI: 8-32; P=0.001) for both groups after 1(st)TACE and by 16cm(3)/TACE (P=0.099) over the full follow-up (up to 9TACEs). Spleen volume also tended to increase by 23cm(3) (95%CI: -1–48; P=0.064) with higher tumor burden. Odds of developing moderate/severe ascites for metastatic patients was decreased by 0.5 (95%CI: 0.3–0.9; P=0.014), regardless of the Child-Pugh, and increased by 1.5 (95%CI: 1.2–1.9; P<0.001) among HCC patients with unstable Child-Pugh, whereas no change was noted with stable Child-Pugh. HCC patients with unstable Child-Pugh demonstrated a significant increase in portosystemic collaterals number over time (P=0.008). PVP-related complications such as variceal bleeding post-TACE were low (0.4%). CONCLUSION: Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602787/ /pubmed/34804911 http://dx.doi.org/10.3389/fonc.2021.639235 Text en Copyright © 2021 Frangakis, Sohn, Bas, Chapiro, Schernthaner, Lin, Hamilton, Pawlik, Hong and Duran https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Frangakis, Constantine
Sohn, Jae Ho
Bas, Ahmet
Chapiro, Julius
Schernthaner, Ruediger E.
Lin, MingDe
Hamilton, James P.
Pawlik, Timothy M.
Hong, Kelvin
Duran, Rafael
Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title_full Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title_fullStr Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title_full_unstemmed Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title_short Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
title_sort longitudinal analysis of the effect of repeated transarterial chemoembolization for liver cancer on portal venous pressure
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602787/
https://www.ncbi.nlm.nih.gov/pubmed/34804911
http://dx.doi.org/10.3389/fonc.2021.639235
work_keys_str_mv AT frangakisconstantine longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT sohnjaeho longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT basahmet longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT chapirojulius longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT schernthanerruedigere longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT linmingde longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT hamiltonjamesp longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT pawliktimothym longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT hongkelvin longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure
AT duranrafael longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure